Investigational drug · Phase 2
EDP167
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia (HoFH).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "EDP167"
First trial start
2026
Feb 6, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDP167", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mixed Dyslipidemia
- Homozygous Familial Hypercholesterolemia (HoFH)
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "EDP167" as an intervention, largest first.
- Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed DyslipidemiaPivotal-lookingNot yet recruiting
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07799129 · 144 participants (planned) · Start Nov 2026 · Primary completion Nov 2027
Drug: EDP167 100mg; EDP167 200mg and 1 more · For: Mixed Dyslipidemia
Sites: Harbin, China; Zhejiang, China
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07412080 · 40 participants · Start Jul 1, 2025 · Primary completion Dec 12, 2025
Drug: EDP167; Placebo · For: Healthy Adult Male and Female Volunteers; Mild Dyslipidemia
Sites: Guangzhou, China; Hangzhou, China
Eddingpharm (Zhuhai) Co., Ltd.Industry
NCT07489209 · 20 participants (planned) · Start Feb 6, 2026 · Primary completion Oct 4, 2026
Drug: EDP167 · For: Homozygous Familial Hypercholesterolemia (HoFH)
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Mixed Dyslipidemia
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- AD-218Phase 31 trial
Addpharma Inc. · Mixed Dyslipidemia
- AD-218APhase 31 trial
Addpharma Inc. · Mixed Dyslipidemia
- DW5421APhase 31 trial
Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia
- DW5421BPhase 31 trial
Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia
- BW-00112Phase 21 trial
Shanghai Argo Biopharmaceutical Co., Ltd. · Mixed Dyslipidemia
- MWX203Phase 21 trial
Shanghai Minwei Biotechnology Co., Ltd · Mixed Dyslipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.